Addition of Pembrolizumab to the Standard of Care Chemotherapy in Patient With SCCOHT
Small cell ovarian carcinomas are rare and have a very poor prognosis affecting a young population. The objective of this study is to increase the efficacy of the initial chemotherapy by providing immunotherapy and to be able to offer to more patients the possibility of benefiting from an intensification of chemotherapy, which is a major prognostic factor in this population.
Small Cell Ovarian Carcinoma
DRUG: Pembrolizumab 25 MG/ML [Keytruda]
Complete response rate, CRR is defined as the proportion of patients who reached complete response (CR), according to RECIST v1.1 after the first sequence therapy including chemotherapy associated with immunotherapy and surgery., Around 4 to 6 months of the last patient included
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability of pembrolizumab in combinaison with chemotherapy], Adverse Events will be described in terms of frequency according to CTCAE v5 grade, 30 days after the end of Cycle 6 (each cycle is 21 days)|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability of pembrolizumab in monotherapy], Adverse Events will be described in terms of frequency according to CTCAE v5 grade, 30 days after last treatment intake|Progression Free Survival (PFS), PFS is defined as the time from inclusion until the date of event defined as the first objective documented progression, according to investigator assessment of RECIST v1.1 or death (by any cause in the absence of progression)., from date of inclusion to date of event, assessed up to 5 years|Overall Survival (OS), OS is defined as the time from the date of inclusion until death due to any cause. Any patient not known to have died at the time of analysis will be censored based on the last recorded date on which the patient was known to be alive., from date of inclusion to death, assessed up to 5 years|Partial Response Rate (PRR), PRR is defined as the proportion of patients who reached partial response (PR), at the end of first-sequence therapy, according to RECIST v1.1., Around 4 to 6 months of the last patient included|Duration of Response (DoR), DOR is defined as the duration from complete response is first met until the first objective documented progression, according to RECIST v1.1., assessed up to 42 months
Small cell ovarian carcinomas are rare and have a very poor prognosis affecting a young population. The objective of this study is to increase the efficacy of the initial chemotherapy by providing immunotherapy and to be able to offer to more patients the possibility of benefiting from an intensification of chemotherapy, which is a major prognostic factor in this population.